All eyes are on drug manufacturers in 2020 as they race to develop the first coronavirus vaccine. Globally, recorded cases of COVID-19 have surpassed 25 million, with at least 847,000 related deaths worldwide. More than 6 million cases have been reported in the U.S. alone, with at least 183,000 deaths as of Aug. 30.
(NASDAQ: MRNA) reported positive results from the phase 1 trial for its COVID-19 mRNA vaccine in July, and started the phase 3 trial on July 27. It’s no surprise that its stock is up 245% year to date, while the S&P 500 has risen just 9%.
under OWS.” data-reactid=”37″>Before this, the U.S. government had already pledged more than $1.5 billion for 100 million doses of Moderna’s potential vaccine, with the option to buy up to an additional 400 million doses under OWS.
View photos
A gloved hand holds up a glass vial labeled “Coronavirus”
Image source: Getty Images.
vaccine development process, many things can go wrong. Vaccines can fail late-stage trials and encounter issues with regulatory approval, and it’s always possible that another drugmaker will come out with a successful vaccine first. ” data-reactid=”67″>Keep in mind that in the vaccine development process, many things can go wrong. Vaccines can fail late-stage trials and encounter issues with regulatory approval, and it’s always possible that another drugmaker will come out with a successful vaccine first.
biotech stock for aggressive investors who believe better rewards come with greater risk.” data-reactid=”87″>Even if another company surpasses Moderna in the vaccine race, the company can still profit from the other drugs in its pipeline — but it could be years before they bring in revenue. That makes Moderna a good biotech stock for aggressive investors who believe better rewards come with greater risk.
Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.” data-reactid=”96″>Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Where Will Moderna Be in 1 Year? was originally published by The Motley Fool” data-reactid=”97″>Where Will Moderna Be in 1 Year? was originally published by The Motley Fool
